Screening For Colorectal Cancer Using Raman Imaging

ChemImage Corporation is pioneering the development of an in vitro diagnostic blood serum assay test using molecular imaging technology called the Raman Assay for Colorectal Cancer (RACC) that provides physicians with a non-invasive, high throughput platform for screening and early detection of polyps and colorectal cancer. The underlying science behind RACC is built upon 20 years of biomedical research using Raman Molecular Imaging (RMI) conducted by ChemImage Corporation. RMI, which is a combination of Raman spectroscopy and digital hyperspectral imaging, is a powerful, high information technology method for the analysis of biological systems.

The Case For Raman Imaging:

Colorectal Cancer is the 3rd most common cancer in the world (1). It is estimated that the disease kills 50,000 Americans and 220,000 Europeans annually (2). If colorectal cancer is detected early, there is a 95% survival rate (3). Early detection, especially of polyps, is critical and has been challenging due to the reluctance of patients to undergo colonoscopy which has been the gold standard for detection. Other tests that are currently available in the market are specific to advanced colorectal cancer and require difficult and unpleasant fecal collection and lack the sensitivity and specificity to provide a definitive diagnosis in the early and most curable stages of the disease. An effective blood test for the detection of polyps and colorectal cancer will impact the management of colorectal disease.

The RACC test is currently in development and is anticipated to change the management of colorectal cancer disease by:

  • Providing the capability of early detection of polyps and colorectal cancer via a non-invasive blood test.
  • Regentless detection on blood serum as an in vitro diagnostic assessment

Clinical testing performed to date indicate RACC's sensitivity and specificity approaches the "gold standard" of the colonoscopy, however, the test is less costly than colonoscopy and genomic tests. Additionally, results can be obtained in minutes, not hours.

Intellectual Property:

At present, there are 16 patents (issued and pending) associated with RACC. These patents were developed by ChemImage Corporation.


1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.